|
Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review |
Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 178. 2016 Authors' objectives To assess the efficacy, comparative effectiveness, and adverse effects of newer drugs to treat lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). Authors' conclusions Several drugs newly used for LUTS attributed to BPH, alone or in combination with older AB, showed evidence of efficacy in short-term studies; however, comparative effectiveness for silodosin, fesoterodine/AB combination, and tadalafil showed that outcomes were similar to older AB monotherapy and adverse effects were often higher with the newly used drugs or combination therapies. Evidence on long-term efficacy and adverse effects was insufficient. Indexing Status Subject indexing assigned by CRD MeSH Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Risk Factors Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32016000833 Date abstract record published 05/07/2016 |
|
|
|